Cibinetide

Summary

Cibinetide (also known as ARA‑290, HBSP) is an investigational peptide derived from the helix‑B region of erythropoietin. It does not stimulate red‑cell production but selectively activates the innate repair receptor (IRR), a heterodimer of the erythropoietin receptor and the β‑common (CD131) subunit. Pre‑clinical work shows anti‑inflammatory and tissue‑protective effects, and early human studies suggest benefits in islet transplantation and small‑fiber neuropathy associated with sarcoidosis.

Mechanism of Action

Cibinetide binds to the IRR (EPOR + CD131) and triggers JAK2‑dependent signalling while avoiding the STAT5 pathway that drives erythropoiesis. Activation leads to downstream PI3K‑AKT and inhibition of NF‑κB p65 activity, reducing production of pro‑inflammatory cytokines, chemokines, and inducible nitric‑oxide synthase. In immune cells, this dampens myeloid activation and limits dendritic‑cell maturation, thereby curbing inflammatory cascades without stimulating red‑cell proliferation.

What the Research Shows

In a mouse model of dextran‑sulphate‑sodium colitis, cibinetide improved weight gain, survival and tissue integrity by limiting myeloid infiltration and NF‑κB‑driven cytokine release. In vitro, LPS‑activated macrophages showed reduced NF‑κB activity dependent on CD131 and JAK2. Human islet studies demonstrated that cibinetide preserved ATP levels, lowered caspase‑3/7 activity, and enhanced insulin secretion under cytokine stress; peri‑operative treatment reduced platelet consumption in an IBMIR model and improved graft insulin output in athymic mice. In an allogeneic mouse islet transplant, daily cibinetide (with or without low‑dose tacrolimus) lowered hepatic inflammation, improved early glycaemic control and delayed graft loss, partly by inhibiting dendritic‑cell maturation. A phase‑2b, 28‑day, randomized trial in 64 sarcoidosis patients with small‑fiber loss reported dose‑related increases in corneal nerve fiber area and skin GAP‑43+ fibers, with associated pain reduction, supporting a disease‑modifying signal. A 2026 review highlighted cibinetide as a non‑erythropoietic EPO derivative with potential neuroprotective roles after traumatic brain injury, but noted that clinical evidence remains preliminary.

Reported Benefits

Pre‑clinical data indicate that cibinetide can attenuate inflammatory bowel disease pathology, protect pancreatic islets from cytokine‑induced death, and improve engraftment after transplantation. Human data from a small sarcoidosis trial suggest it can increase small‑fiber density in cornea and skin and alleviate neuropathic pain, pointing to possible disease‑modifying activity in neuropathy. The peptide also appears to synergise with low‑dose tacrolimus to prolong islet graft survival in mice.

Limitations of the Evidence

Evidence for most indications rests on animal models; human data are limited to a single small, short‑duration trial in sarcoidosis‑associated neuropathy. No large‑scale or long‑term clinical trials have been reported for inflammatory bowel disease, islet transplantation, or neuroprotection. The therapeutic window, optimal dosing, and durability of benefit remain undefined, and the investigational status means regulatory approval has not been granted for any indication.

Safety Considerations

Across the reported studies, no serious adverse events or thrombotic complications were observed, consistent with cibinetide’s non‑hematopoietic design. However, safety data are confined to short‑term animal experiments and a 28‑day human trial, so rare or delayed effects have not been characterised. As an investigational peptide, its use should be limited to controlled research settings until broader safety profiling is available.

How It Is Administered

Cibinetide is formulated for parenteral use and has been administered intravenously or subcutaneously in pre‑clinical studies. In the human sarcoidosis trial, daily subcutaneous injections of 1, 4 or 8 mg were employed for 28 days. Pre‑operative and daily subcutaneous dosing (≈120 µg/kg) has been used in mouse islet‑transplant models. Formulation details beyond route and dosing frequency are not disclosed in the abstracts.

Routes of Administration

Goals & Uses

• Ischemia‑reperfusion injuryTissue ProtectionLow
• Metabolic improvement in type 2 diabetes-associated neuropathyMetabolic / EndocrineLow
• Reduction of painful small fiber neuropathy symptomsNeurological / PainModerate
• Neuroprotection and nerve fiber regenerationNeurologicalModerate
• SarcoidosisInflammatory DiseaseModerate
• Anti-inflammatory effects in sarcoidosisInflammatory / AutoimmuneModerate
• Diabetic peripheral neuropathyNeuropathyModerate
• Ischemia-reperfusion organ protectionOrgan ProtectionLow

Contraindications

• Active malignancyOncologyModerateUse caution or avoid depending on agent and context
• Known hypersensitivity to cibinetide or excipientsAllergy / HypersensitivityHigh

Adverse Effects

• Injection site reactionsLocalCommon
• HeadacheNeurologicUncommonPain in the head or upper neck
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
• FatigueGeneralUncommonLow energy or tiredness
• Injection site erythemaLocalCommonRedness at the injection site

Drug Interactions

• Immunosuppressants (e.g., corticosteroids, methotrexate)Low
• Erythropoiesis-stimulating agents (ESAs)Low
• Erythropoiesis‑stimulating agentsLow

Population Constraints

• PregnancyReproductive SafetyRelative
• Pediatrics (<12 y)AgeRelative
• Severe renal impairmentOrgan ImpairmentRelative
• Pediatric patientsAgeRelative
• Patients with known thromboembolic riskCardiovascularRelative

Regulatory Status

• European UnionInvestigationalClinical trial authorisation pending
• RUInvestigationalPhase II study conducted in Russia
• United StatesInvestigationalIND in place; Phase II/III trials ongoing
• United KingdomUnknownNo confirmed regulatory designation or approval in the UK post-Brexit; status follows EMA precedent historically.

Not approved by FDA, EMA or other major agencies; currently in Phase II/III clinical trials in several countries.

Evidence & Sources

• Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis
  Journal ArticleLowNairz M, et al.2017-01-01T00:00:00.000000Z
• Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation
  Journal ArticleLowYao M, et al.2021-01-01T00:00:00.000000Z
• The time to develop treatments for diabetic neuropathy
  Journal ArticleHighRendell MS2021-01-01T00:00:00.000000Z
• Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand
  Journal ArticleLowYao M, et al.2020-01-01T00:00:00.000000Z
• Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain
  Journal ArticleModerateCulver DA, et al.2017-01-01T00:00:00.000000Z
• Phase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy
  Journal ArticleModerateSun Y, et al.2025-01-01T00:00:00.000000Z

Frequently Asked Questions